Okeiro, formerly Predict4Health and based in Paris, builds an advanced clinical decision support platform that leverages AI to prevent organ failure across kidney, lung, heart and liver transplants and advanced chronic diseases. At the core of the platform is the iBox algorithm, a clinically validated predictive model developed with APHP and INSERM that is marked as a medical device and qualified as a surrogate endpoint by the FDA and EMA. The technology enables physicians to identify post-transplant complications, improve patient monitoring and treatment protocols, and accelerate clinical trial timelines. The platform is already implemented in transplant centers across France, is benefiting thousands of patients, and has achieved national reimbursement through the French National Health Insurance. Okeiro is currently running a randomized clinical trial across 16 hospital centers in six countries (France, Germany, the United Kingdom, Austria, Israel and Spain) to compare outcomes for physicians using the platform versus standard care; interim results are very positive and the study will complete in a few months. The company plans to use the newly raised funds to accelerate deployment in France and internationally and to develop new AI tools to further improve diagnostics, therapeutic recommendations, and clinical research in end-stage chronic disease and transplant patients.

Total raised

$12M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2025